两分次立体定向消融放疗同步加量至MRI定义的前列腺内优势病灶——2SMART 2期试验结果
2SMART 2期试验首次报告两分次立体定向消融放疗(SABR)同步加量至MRI定义的前列腺内优势病灶(DIL)治疗局限性前列腺癌的安全性。30例低危或中危前列腺癌患者入组,中位随访44个月,中位PSA最低值0.25 ng/mL,无≥3级急性和晚期泌尿或肠道毒性。
要点
- 两分次前列腺SABR同步加量至MRI定义DIL,处方剂量GTV 32 Gy、CTV 26 Gy,安全可行。
- 30例患者中10例(33%)出现泌尿、6例(20%)肠道、3例(10%)性功能QOL急性最小临床重要改变。
- 中位随访44个月,仅1例(3%)在治疗后44个月出现生化失败,无≥3级泌尿或肠道毒性。
核心结论
- 两分次前列腺SABR同步加量至MRI定义DIL是一种安全的剂量递增方案,对急性QOL影响轻微,且未观察到≥3级毒性。
研究设计与样本
- 2SMART 2期试验首次报告,纳入低危或中危局限性前列腺癌男性患者。
- GTV为MRI定义的DIL,CTV为整个前列腺,PTV前后左右外扩2 mm、上下外扩2.5 mm。
- 处方剂量为GTV 32 Gy、CTV 26 Gy。
- 主要终点为SABR后3个月内使用EPIC-26问卷评估的QOL最小临床重要改变(MCIC)。
- 次要终点为急性和晚期毒性(CTCAEv4评估)、PSA最低值和生化失败(Phoenix标准)。
主要发现
- 共30例患者入组,其中低危2例(7%)、中危28例(93%)。
- 中位随访44个月(范围39-49个月)。
- 中位PSA最低值为0.25 ng/mL,中位达最低值时间为37个月。
- 1例(3%)在治疗后44个月出现生化失败。
- 泌尿、肠道和性功能QOL域出现急性MCIC的患者分别为10例(33%)、6例(20%)和3例(10%)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: This is the first report of the 2SMART Phase II trial evaluating the safety of two-fraction stereotactic ablative radiotherapy (SABR) with focal boost to magnetic resonance imaging (MRI) defined dominant intra-prostatic lesion (DIL) for localised prostate cancer. MATERIALS AND METHODS: Men with low or intermediate risk prostate cancer were eligible for the study. The gross tumour volume (GTV) was MRI-defined DIL, and the clinical target volume (CTV) was entire prostate gland. The planning target volume (PTV) was a 2 mm expansion anteroposterior and lateral, and 2.5 mm superoinferior. The prescribed dose was 32 Gy to GTV, and 26 Gy to CTV. Primary endpoint was minimal clinically important change (MCIC) in quality of life (QOL) within 3-months of SABR, assessed using the EPIC-26 questionnaire. Secondary endpoints were acute and late toxicities (assessed using CTCAEv4), PSA nadir, and biochemical failure (based on Phoenix criteria). RESULTS: Thirty men were enrolled in the study - 2 (7%) had low-risk and 28 (93%) had intermediate risk prostate cancer. The median follow-up was 44 months (range:39-49 months). The median PSA nadir was 0.25 ng/mL, with median time to nadir of 37 months. One patient (3%) had biochemical failure at 44 months post-treatment. Ten (33%), six (20%), and three (10%) men had acute MCIC in urinary, bowel, and sexual QOL domains respectively. No acute or late grade ≥ 3 urinary or bowel toxicities were observed. CONCLUSION: This novel protocol of two-fraction prostate SABR with MRI-defined DIL boost is a safe approach for dose-escalation, with minimal impact on acute QOL and no grade ≥ 3 toxicities.
引用
- Ong WL, Cheung P, Chung H, et al. Two-fraction stereotactic ablative radiotherapy with simultaneous boost to MRI-defined dominant intra-prostatic lesion - Results from the 2SMART phase 2 trial. Radiother Oncol. 2023. PMID: 36754232. doi:10.1016/j.radonc.2023.109503
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。